Are Genus plc And Dechra Pharmaceuticals plc Better Buys Than GlaxoSmithKline plc?

Which of these 3 pharmaceutical companies should you add to your portfolio? Genus plc (LON: GNS), Dechra Pharmaceuticals plc (LON: DPH) or GlaxoSmithKline plc (LON: GSK)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

While shares in GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) have disappointed in the last year, it has not been the same story for a number of its pharmaceutical rivals. In fact, shares in Genus (LSE: GNS) and Dechra (LSE: DPH) have soared in the last 12 months by 35% and 55% respectively, which is a much healthier return than GlaxoSmithKline’s fall of 6%.

Does this mean, then, that Genus and Dechra are better buys that GlaxoSmithKline? Or, is their larger peer now better value for long term investors?

Margin Of Safety

Suffice to say, it is rare to find a pharmaceutical company that offers a wide margin of safety. That’s even more the case when comparing them to the wider market, since they tend to offer stronger growth in the long run, while their lack of strong correlation to the macroeconomic outlook marks them out as strong defensive plays. So, while all three companies trade at premiums to the FTSE 100, their margins of safety still differ somewhat.

For example, Genus and Dechra currently trade on price to earnings (P/E) ratios of 25.6 and 26.1 respectively, which are significantly higher than the FTSE 100’s P/E ratio of around 16. Certainly, both companies are set to increase their bottom lines at a much faster rate than the wider index, with growth of 16% in the current year and 12% next year pencilled in for Genus. Meanwhile, Dechra is expected to grow its profit by 8% this year and 11% in the following year.

The problem, though, is that these above average growth rates appear to be adequately priced in – especially after their aforementioned share price rises in the last year. As such, there is little margin of safety, which could mean that share price growth is not as impressive as the market is currently anticipating.

GlaxoSmithKline, of course, is lacking significant growth appeal over the next couple of years. In fact, its bottom line is forecast to fall by 4% this year before recovering by 3% next year. So, compared to Genus and Dechra, it is expected to post disappointing results. However, GlaxoSmithKline trades on a much lower rating than its two smaller peers, with it having a P/E ratio of just 16.8. This indicates that if the company is able to deliver on the efficiencies it has planned and which are set to catalyse its bottom line, its valuation has scope to move substantially upwards.

Total Return

Of course, with sales and earnings of pharmaceutical companies being relatively volatile, an income element to total return can be highly worthwhile for investors. In this space, GlaxoSmithKline is the clear winner of the three companies, since it has a dividend yield of 5.3% at the present time. This compares favourably to Genus and Dechra, which have yields of just 1.4% and 1.6% respectively.

And, looking ahead, the total return from GlaxoSmithKline could be higher than that of Genus or Dechra, since it offers a much cheaper share price. And, from next year, it is expected to return to growth, which could act as a catalyst on investor sentiment. So, while Genus and Dechra have massively outperformed GlaxoSmithKline in the last year, the tables could turn for investors taking a long term view.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »